Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.

Bouchard, C ; Labrie, F ; et al.

In: Hormone molecular biology and clinical investigation, Jg. 25 (2016-03-01), Heft 3, S. 181

academicJournal

Objective: Intravaginal DHEA (dehydroepiandrosterone, prasterone), the exclusive precursor of androgens and estrogens in postmenopausal women, has previously been shown to improve all the domains of sexual function by a strictly local action in the vagina. The well recognized female sexual function index (FSFI) questionnaire was used in the present study.

Design: The long-term effect of 52-week treatment with daily intravaginal 0.50% (6.5 mg) DHEA was evaluated on the various domains of female sexual function using the FSFI questionnaire at baseline, Week 26 and Week 52.

Subjects: One hundred and fifty-four postmenopausal women with at least one mild to severe symptom of vulvovaginal atrophy (VVA) and who have completed the FSFI questionnaire at baseline and at least one post-baseline timepoint were included in the analysis.

Results: The FSFI domains desire, arousal, lubrication, orgasm, satisfaction and pain were increased by 28%, 49%, 115%, 51%, 41% and 108%, respectively (p<0.0001 for all parameters) at 52 weeks vs. baseline, while the total score was increased from 13.4±0.62 at baseline to 21.5±0.82 (+60%, p<0.0001) at 52 weeks.

Conclusion: As the serum levels of DHEA and all its metabolites, including estradiol and testosterone, show no meaningful change, the present clinical data indicate a stimulatory effect of intravaginal DHEA through a strictly local action in agreement with the preclinical data showing that the androgens made locally from DHEA in the vagina induce an increase in local nerve density.

Titel:	Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Autor/in / Beteiligte Person:	Bouchard, C ; Labrie, F ; Derogatis, L ; Girard, G ; Ayotte, N ; Gallagher, J ; Cusan, L ; Archer, DF ; Portman, D ; Lavoie, L ; Beauregard, A ; Côté, I ; Martel, C ; Vaillancourt, M ; Balser, J ; Moyneur, E
Zeitschrift:	Hormone molecular biology and clinical investigation, Jg. 25 (2016-03-01), Heft 3, S. 181
Veröffentlichung:	Berlin : De Gruyter, 2016
Medientyp:	academicJournal
ISSN:	1868-1891 (electronic)
DOI:	10.1515/hmbci-2015-0044
Schlagwort:	Administration, Intravaginal Adult Aged Dehydroepiandrosterone administration & dosage Dehydroepiandrosterone adverse effects Double-Blind Method Female Humans Middle Aged Orgasm drug effects Placebo Effect Surveys and Questionnaires Dehydroepiandrosterone therapeutic use Postmenopause drug effects Sexual Dysfunction, Physiological drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Corporate Authors: VVA Prasterone Group Publication Type: Clinical Trial, Phase III; Journal Article Language: English [Horm Mol Biol Clin Investig] 2016 Mar; Vol. 25 (3), pp. 181-90. MeSH Terms: Dehydroepiandrosterone / therapeutic use ; Postmenopause / drug effects ; Sexual Dysfunction, Physiological / *drug therapy ; Administration, Intravaginal ; Adult ; Aged ; Dehydroepiandrosterone / administration & dosage ; Dehydroepiandrosterone / adverse effects ; Double-Blind Method ; Female ; Humans ; Middle Aged ; Orgasm / drug effects ; Placebo Effect ; Surveys and Questionnaires Contributed Indexing: Investigator: K Aqua; DF Archer; N Ayotte; G Bachmann; M Baron; S Bélisle; S Berg; R Beyer; S Blank; F Blouin; C Bouchard; L Cusan; L Derogatis; J Gallagher; A Gangestad; N Giguère; G Girard; C Goldberg; S Goldstein; B Hauck; A Kaunitz; A Khaled; J Kirstein; W Koltun; B Levine; S Levine; AS Lukes; M Martens; J McClinton; J Pinkerton; DJ Portman; J Rice; J Simon; S Swanson; M Turner; S Varano; A Wade; AS Waldbaum; A Weisz; A Wine; D Young Substance Nomenclature: 459AG36T1B (Dehydroepiandrosterone) Entry Date(s): Date Created: 20160105 Date Completed: 20161213 Latest Revision: 20161230 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.